The primary outcome comprising mortality, ventricular fibrillation and/or heart failure at 90 days has not been statistically different when the following comparisons were made: primary PTCA with GP IIb/IIIa inhibitors in the laboratory vs GP IIb/IIIa inhibitors and a half dose of reteplase pre-laboratory and GP IIb/IIIa inhibitors pre-laboratory vs GP IIb/IIIa inhibitor and a half dose of reteplase pre-laboratory; however, there was a higher incidence p< 0.005 of major and minor hemorrhage according to the TIMI criterion for the two groups of facilitated angioplasty GP IIb/IIIa inhibitor pre PTCA and half dose of reteplase with GP IIb/IIIa inhibitor pre-PTCA as compared with primary PTCA.
El desenlace primario de mortalidad, fibrilación ventricular y/o insuficiencia cardiaca tras 90 días no resultó estadísticamente distinta entre las comparaciones -ATC primaria con IG IIb/IIIa en el laboratorio vs IG IIb/IIIa y media dosis de reteplase prelaboratorio; y IG IIb/IIIa prelaboratorio x IG IIb/IIIa y media dosis de reteplase prelaboratorio. Hubo mayor incidencia p<0,005 de hemorragias mayores y menores, según el criterio TIMI, para los dos grupos de angioplastia facilitada -IG IIb/IIIa pre-ATC y media dosis de reteplase com. IG IIb/IIIa pre-ATC-, si comparados con ATC primaria.
Tais resultados não trazem muito otimismo para esse tipo de estratégia.